You are about to leave the Clinical Value website now.


No time to wait: Evolving testing & treatment landscape in early stage lung cancer

Lung cancer has seen tremendous advancements over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors. Until recently, these advances were predominantly in the advanced metastatic setting. The approvals of osimertinib, the first targeted therapy directed against EGFR for adjuvant use and atezolizumab , the first immune-checkpoint inhibitor to be FDA-approved for adjuvant use have brought much needed advancement in the post-operative setting. Please join our live webinar on 10th August to hear thoracic multidisciplinary teams of pathologists, surgeons and oncologists from Korea and Thailand share updates in the testing and treatment setting for early stage non-small cell lung cancer.


Dr. Min-Hee Hong, MD

Associate Professor, Division of Medical Oncology, Department of Internal Medicine Yonsei Cancer Center, Severance Hospital
Yonsei University College of Medicine Seoul, Korea


Dr. Tae-Jung Kim

Professor, Department of Hospital Pathology, Yeouido St. Mary’s hospital, The Catholic University of Korea, Seoul, Korea

Dr. Pimpin Incharoen, MD

Assistant Professor, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Dr. Somcharoen Saeteng

Associate Professor, Thoracic Surgeon, Chiang Mai University, Chiang Mai, Thailand


This content is targeted at healthcare professionals and could contain information otherwise not accessible, approved or valid in your country. Please be aware that we do not take any responsibility for you accessing information which may not comply with any legal process, regulation, registration or usage in the country of your origin.This content is for general information purposes only. We disclaim all liability and are not responsible for any third party content on our website or which our website links to.

Be the first to receive updates, event opportunities, and thought leadership insights.